Ildefonso Sánchez‐Cerrillo

Author

Hospital Universitario de La Princesa ORCID

Also Known As

Enrique Martín, Francisco Sánchez-Madrid, I Sánchez-Cerrillo, I. Sánchez-Cerrillo, Ildefonso Sanchez-Cerrillo, Ildefonso Sánchez-Cerrillo, Ildefonso Sánchez‐Cerrillo, Roser Font, Tamara Mateu-Albero, V Sánchez

Publications

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario de La Princesa Universidad Autónoma de Madrid Centro de Investigación Biomédica en Red Instituto de Salud Carlos III Universitat Autònoma de Barcelona

About

Ildefonso Sánchez‐Cerrillo is an author at Hospital Universitario de La Princesa specializing in immune regulation, autoimmune disease, and immune system.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	27
2	Immunology	2	2	27
3	Cell Biology	1	1	16
4	Clinical Immunology	1	1	11
5	Rheumatology	1	1	16

Ildefonso Sánchez‐Cerrillo

Publications

723

Citations

H-Index

Page 1

	Year	Citations
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study José María Galván‐Román, S. C. Rodriguez-García, Emilia Roy‐Vallejo, Journal of Allergy and Clinical Immunology	2020	231
COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes Ildefonso Sánchez‐Cerrillo, Pedro Landete, Beatriz Aldave, Journal of Clinical Investigation	2020	211
Differential Redistribution of Activated Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19 Ildefonso Sánchez‐Cerrillo, Pedro Landete, Beatriz Aldave,	2020	71
Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID‐19 patients Ana Marcos‐Jiménez, Santiago Sánchez‐Alonso, Ana Alcaraz‐Serna, European Journal of Immunology	2020	42
Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events Javier Martínez‐Sanz, Jorge Díaz-Álvarez, Marta Rosas Cancio-Suárez, EBioMedicine	2023	32
KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir Antonio Astorga-Gamaza, David Perea, Nerea Sánchez-Gaona, Cell Reports Medicine	2023	31
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice Inés Suárez‐García, Belén Alejos, Víctoria Hernando, Journal of Antimicrobial Chemotherapy	2023	26
Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV Marta Calvet‐Mirabent, Ildefonso Sánchez‐Cerrillo, Noa B. Martín‐Cófreces, EBioMedicine	2022	24
Poly I:C and STING agonist‐primed DC increase lymphoid tissue polyfunctional HIV‐1‐specific CD8 <sup>+</sup> T cells and limit CD4 <sup>+</sup> T‐cell loss in BLT mice Marta Calvet‐Mirabent, Daniel T. Claiborne, Maud Déruaz, European Journal of Immunology	2021	17
NLRC4-mediated activation of CD1c+ DC contributes to perpetuation of synovitis in rheumatoid arthritis Cristina Delgado‐Arévalo, Marta Calvet‐Mirabent, Ana Triguero‐Martínez, JCI Insight ImmunologyImmune RegulationCd4 T Cell ResponsesInnate ImmunityNlrc4-mediated Activation	2022	16

Page 1